Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1976 1
1978 3
1982 1
1983 3
1984 3
1985 6
1986 6
1987 3
1989 1
1990 1
1991 2
1992 4
1993 2
1994 1
1995 1
1996 2
1997 4
1998 12
1999 6
2000 9
2001 10
2002 7
2003 9
2004 7
2005 10
2006 12
2007 13
2008 13
2009 11
2010 11
2011 11
2012 3
2013 7
2014 4
2015 4
2016 4
2017 7
2018 4
2019 8
2020 4
2021 5
2022 7
2023 2
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

239 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, Hájek R, Liu Z, Minarik J, Moreau P, Romejko-Jarosinska J, Spicka I, Vorobyev VI, Besemer B, Ishida T, Janowski W, Kalayoglu-Besisik S, Parmar G, Robak P, Zamagni E, Goldschmidt H, Martin TG, Manier S, Mohty M, Oprea C, Brégeault MF, Macé S, Berthou C, Bregman D, Klippel Z, Orlowski RZ; IMROZ Study Group. Facon T, et al. N Engl J Med. 2024 Oct 31;391(17):1597-1609. doi: 10.1056/NEJMoa2400712. Epub 2024 Jun 3. N Engl J Med. 2024. PMID: 38832972 Clinical Trial.
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351. Usuki K, et al. Among authors: katsuoka y. Int J Hematol. 2024 Jun;119(6):647-659. doi: 10.1007/s12185-024-03733-z. Epub 2024 Mar 26. Int J Hematol. 2024. PMID: 38532078 Free PMC article. Clinical Trial.
Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT.
Nakagawa N, Ishiyama K, Usuki K, Takada S, Tomikawa T, Handa H, Katsuoka Y, Hirano D, Sezaki N, Sumi M, Fujisawa S, Taniguchi Y, Mugitani A, Yoshimura T, Ohtsuka E, Takase K, Suehiro Y, Ota S, Kajiguchi T, Maeda T, Yamamoto M, Ohtake S, Katsumi A, Kiyoi H, Matsumura I, Miyazaki Y. Nakagawa N, et al. Among authors: katsuoka y. Ann Hematol. 2024 Jan;103(1):307-320. doi: 10.1007/s00277-023-05527-5. Epub 2023 Nov 8. Ann Hematol. 2024. PMID: 37940714
[Molecular targeting therapy for bladder cancer].
Azuma H, Katsuoka Y. Azuma H, et al. Among authors: katsuoka y. Hinyokika Kiyo. 2008 Jan;54(1):67-75. Hinyokika Kiyo. 2008. PMID: 18260365 Free article. Review. Japanese.
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Mori Y, Takizawa J, Katsuoka Y, Takezako N, Nagafuji K, Handa H, Kuroda J, Sunami K, Kamimura T, Ogawa R, Kikushige Y, Harada M, Akashi K, Miyamoto T; Japan Study Group for Cell Therapy and Transplantation. Mori Y, et al. Among authors: katsuoka y. Cancer Sci. 2024 Jun;115(6):2002-2011. doi: 10.1111/cas.16158. Epub 2024 Mar 18. Cancer Sci. 2024. PMID: 38498976 Free PMC article. Clinical Trial.
Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study.
Kurita N, Imahashi N, Chiba S, Tanaka M, Kobayashi H, Uchida N, Kuriyama T, Anzai N, Nawa Y, Nakano N, Ara T, Onizuka M, Katsuoka Y, Koi S, Kimura T, Ichinohe T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy. Kurita N, et al. Among authors: katsuoka y. Am J Hematol. 2024 Feb;99(2):236-244. doi: 10.1002/ajh.27172. Epub 2024 Jan 2. Am J Hematol. 2024. PMID: 38165068
Metastases to the penis from carcinoma of the prostate.
Kotake Y, Gohji K, Suzuki T, Watsuji T, Kusaka M, Takahara K, Ubai T, Noumi H, Inamoto T, Shibahara N, Ueda H, Katsuoka Y. Kotake Y, et al. Among authors: katsuoka y. Int J Urol. 2001 Feb;8(2):83-6. doi: 10.1046/j.1442-2042.2001.00245.x. Int J Urol. 2001. PMID: 11240832 Free article. Review.
[Human heparanase: roles in invasion and metastasis of cancer].
Gohji K, Katsuoka Y, Okamoto M, Kamidono S, Kitazawa S, Toyoshima M, Dong J, Nakajima M. Gohji K, et al. Among authors: katsuoka y. Hinyokika Kiyo. 2000 Oct;46(10):757-62. Hinyokika Kiyo. 2000. PMID: 11215206 Free article. Review. Japanese.
Gemicitabine resistence and mesenchymal phenotype.
Inamoto T, Azuma H, Katsuoka Y. Inamoto T, et al. Among authors: katsuoka y. Ann Surg Oncol. 2009 May;16(5):1435-6. doi: 10.1245/s10434-008-0309-0. Epub 2009 Jan 29. Ann Surg Oncol. 2009. PMID: 19184229 No abstract available.
239 results